Scientists of Ambedkar Hospital have developed such a biomarker kit, which can estimate the severity of the disease in the initial stage of COVID-19
Raipur. With the aim of developing and strengthening the health research infrastructure in the country, a team of scientists of the Multi-Disciplinary Research Unit (MRU/ Multi-Disciplinary Research Unit) established at Dr. Bhimrao Ambedkar Smriti Hospital Raipur has developed such a biomarker kit which will estimate the severity of the COVID-19 pandemic infection in the initial stage itself. The results of this research, which started from the initial stage of COVID-19, have recently been published in the science journal Scientific Reports (https://www.nature.com/articles/s41598-024-70161-8) which is published by the prestigious Nature Publishing Group. It is the 5th most referenced research journal in the world in the field of research.
At the beginning of the pandemic, while many leading scientists of the country were engaged in developing new COVID-19 diagnostic test kits, the corresponding author (Principal Investigator) of the research publication, Dr. Jagannath Pal (MBBS, PhD, Postdoc from Harvard Cancer Institute (Boston USA)), Senior Scientist, MRU, started thinking in the direction of the above basic issue of management of the COVID-19 pandemic, which can also be used to deal with any pandemic situation in future.
According to Dr. Jagannath Pal, the lead scientist and team leader who developed the COVID-19 Prognostic Biomarker Kit (prediction of disease severity at an early stage), in the initial phase of the corona epidemic, resources and anti-virus drugs were used in large quantities, which led to a serious drug crisis as well as a crisis of life-saving drugs like Remdesivir. In the initial stage, it was difficult to find out which corona patients needed advance medical facilities or not? Therefore, it was necessary to divide the severity of infection of patients into different categories based on the predicted result so that these resources could be used in severe corona patients, but at that time there was no such test/examination available which could detect the severity of corona patients in the early stage itself.
Success achieved after three years of tireless work
The MRU research team led by Dr. Pal started working in this direction using the limited resources available and eventually succeeded in developing a biomarker kit, using which the severity of corona can be predicted in the early stage itself. In this research work, the scientists developed a severity score using a q PCR (Quantitative PCR) based test which has a sensitivity of 91 percent and specificity of 94 percent. Dr. Yogita Rajput, another MRU scientist in this research team, the first author of the paper, played a key role in bringing the challenging project to life by coordinating with other multidisciplinary contributors from various departments.
Considering the potential commercial value of Dr. Pal’s invention, Pt. JNM Medical College has applied for an Indian patent as well as an international patent. According to Dr. Pal, recently the US Patent Search Agency has provided encouraging reports indicating the potential commercial significance of the invention in the US. This means that we can get an opportunity to export medical technology abroad contributing to India’s economic growth. MRU’s research will also sustain the Make in India campaign of our country’s Prime Minister. Contrary to the common belief that such technology requires large infrastructure, large funds and manpower to invent. The success story is also an inspiring example for many researchers working in resource limited centers. The achievement of Pt. JNM Medical College will set an encouraging example that a state-run medical college is developing medical technology to meet the need of the hour and is also contributing to its commercialization.
